Vagus Nerve Relief

Last updated 2026-10-03 · updated weekly by an automated research job · run #10.

The verdict

The current state of the art, as of 2026-08-18 (confidence unverified):

The current state of the art for non-invasive, consumer-accessible vagus nerve interventions is fragmented across modalities, with no single device demonstrating clear, replicated superiority across the beat's target outcomes. Electrical taVNS devices like Nurosym hold CE-marked medical device status in the EU, while photobiomodulation approaches like the Vielight Vagus offer a non-electrical alternative with recent patent awards. The evidence base consists primarily of vendor claims, small studies, and open-label trials; a systematic review found no significant benefit of VNS over sham for depression.

What triggered or contributed to this call:

• 2026-08-18 — Nurosym claims CE-marked status for home-use auricular tVNS. (regulatory, vendor-claim)
• 2026-08-18 — Vielight awarded patent for photobiomodulation-based vagus nerve stimulation device. (update, secondary)
• 2026-08-18 — Systematic review finds no significant difference between VNS and sham for depression. (negative, secondary)

Contenders:

• Nurosym — Holds CE-marked medical device status for home-use auricular tVNS in the EU/UK.
• tVNS Technologies GmbH — Device is approved as a Class IIa medical device under EU-MDR and used in clinical trials.
• Vielight Vagus — Offers a patented, non-electrical photobiomodulation approach targeting the vagus nerve.
• gammaCore — FDA-cleared non-invasive cervical VNS device for a specific medical indication (cluster headache).
• Pulsetto — Commercially available cervical wearable with cited pilot study data and CE/FCC certification.

What this is, and how it works

This page is generated, not written. A scheduled job runs weekly on a machine in a homelab. Each run it:

1. Searches the open web for both the products already tracked here and for category-level terms designed to turn up ones we've never heard of.
2. Feeds those results to a language model along with everything already on this page, and asks it what is genuinely new. Finding nothing is an acceptable answer, and most runs should find little.
3. Writes the result into a versioned JSON dataset (data/live-research/vagus.json) and commits it. This page is re-rendered from that file.

So: a machine wrote the prose here. Every changelog entry carries at least one source link, and every item and entry carries a confidence label:

• primary-source — vendor documentation, a published paper, or a regulator.
• secondary — reputable press.
• vendor-claim — marketing or an unreplicated vendor statement.
• unverified — a single low-quality source, usually auto-discovered.

Any label weaker than primary-source is printed beside the finding, so an unflagged row is a primary source. A tracker that hides its own uncertainty is worse than no tracker.

What this is not. Not medical advice. Not a review site — nothing here has been tested in our hands. No affiliate relationships, no sponsored placements, nothing bought. Vendor claims are attributed to the vendor rather than restated as findings. Where a price, a date, or a regulatory status is unknown, it is left blank instead of guessed.

What's new

20 developments in the last 30 days, newest first.

The last 30 days

Hoolest and Pulsetto are pushing discounts for October and Black Friday 2026, respectively, indicating promotional pressure in the consumer segment. Pulsetto also launched its next-generation FIT X wearable with a new bilateral electrode design and, in a vendor-claimed blog post, cited a pilot study suggesting its bilateral stimulation reduced hair cortisol more than unilateral stimulation after four weeks. Meanwhile, the implantable SetPoint System saw its first reported use in New Jersey for rheumatoid arthritis, a concrete but isolated clinical adoption.

On the research front, the last 30 days brought a cluster of new primary studies on transcutaneous auricular vagus nerve stimulation (taVNS). One open-label pilot showed reduced autonomic symptoms in hypermobile Ehlers-Danlos patients, and a randomized, sham-controlled study found taVNS improved executive control after high cognitive load. A comprehensive review also summarized the field's mechanisms and applications. These add to the evidence base but remain early-stage.

For tracked products with no developments, note their silence. Vielight's Vagus and AI platform pages were confirmed but show no new activity; the AI platform remains a vendor-claimed concept without a confirmed launch. The SONA AI VNS system still has no primary source or product page. ElectroCore's gammaCore faced a stock plunge after an FDA request for more data, though its existing clearances stand. The Evren Phoenix CR launched as a research tool, and the Vagustim V2 page was discovered, but both are unverified for consumer use. If you're considering a purchase, the discounting and new model from Pulsetto represent the most tangible consumer-facing moves this month, against a backdrop of steady academic research progress.

Written 2026-10-03 from the changelog below, not from a fresh search.

Drawn from:

• SetPoint System used for rheumatoid arthritis at New Jersey medical center. — 2026-10-03, confidence secondary
• Pulsetto cites pilot study showing bilateral stimulation reduced hair cortisol. — 2026-10-03, confidence vendor-claim
• Comprehensive review of taVNS mechanisms and applications published. — 2026-10-03, confidence primary-source
• taVNS pilot study shows improvement in dysautonomia for hypermobile Ehlers-Danlos patients. — 2026-10-03, confidence primary-source
• taVNS improves executive control after high cognitive load in randomized study. — 2026-10-03, confidence primary-source
• Pulsetto launches FIT X, a next-generation wearable with redesigned bilateral electrode. — 2026-09-21, confidence vendor-claim
• Vagustim V2 product page confirms it as a non-invasive, ear-based VNS device. — 2026-09-21, confidence vendor-claim
• ElectroCore's stock plunges after FDA requests more data on GammaCore. — 2026-09-21, confidence secondary
• No primary source found for SONA AI VNS system; LinkedIn points to unrelated companies. — 2026-09-21, confidence unverified
• Evren Technologies launches Phoenix CR taVNS research device. — 2026-09-14, confidence vendor-claim
• Pulsetto surpasses $40M in revenue and secures EU funding for trials. — 2026-09-14, confidence vendor-claim
• Vielight-AI platform page includes wellness disclaimer, not confirming commercial launch. — 2026-09-14, confidence vendor-claim
• gammaCore non-invasive VNS device FDA-cleared for episodic cluster headache in 2017. — 2026-09-14, confidence primary-source
• MAESTRO Rechargeable system for vagal-blocking therapy discontinued in U.S. market. — 2026-09-14, confidence secondary
• Clinical trial registered to test Soterix Medical taVNS device for delirium. — 2026-09-07, confidence primary-source
• University magazine article highlights the transformative potential of taVNS. — 2026-09-07, confidence secondary
• Vielight Vagus product page confirms device specifications and marketing claims. — 2026-09-07, confidence vendor-claim
• Vielight-AI platform is listed as 'New' on Vielight's science blog. — 2026-09-07, confidence vendor-claim
• Primary product page found for Xen by Neuvana, confirming commercial availability. — 2026-09-07, confidence vendor-claim
• Primary website found for Pulsetto, confirming it as a cervical VNS wearable. — 2026-09-07, confidence vendor-claim

The last year

The last year saw a clear split between the clinical and consumer sides of non-invasive vagus nerve stimulation. On the clinical research front, evidence continued to accumulate for transcutaneous auricular vagus nerve stimulation (taVNS). A pilot study in hypermobile Ehlers-Danlos patients found eight weeks of taVNS significantly reduced autonomic symptom scores, and another randomized study showed it improved executive control after high cognitive load. A comprehensive review in Frontiers in Neurology also summarized the growing mechanistic and clinical landscape. However, a systematic review noted no significant difference between VNS and sham for depression, underscoring that outcomes are condition-specific and not universally positive. Tools for this research became more specialized, with Soterix Medical and Evren Technologies both launching new taVNS devices explicitly designed as configurable research tools for clinical studies.

In the regulated medical device space, the year brought both a major approval and a significant setback. The FDA approved the implantable SetPoint System for rheumatoid arthritis, a landmark event with its first clinical use in New Jersey reported this October. Conversely, ElectroCore's stock plunged after the FDA requested more data on its non-invasive gammaCore device, though it remains cleared for cluster headache. A Class 2 recall was also issued for LivaNova's implantable SenTiva generator due to a risk of it stopping stimulation entirely. In Europe, tVNS Technologies GmbH emphasized its device's status as a Class IIa medical device under the EU-MDR and launched a new "Triggerbox" to reduce latency for research synchronization.

The consumer wellness market, operating largely on vendor claims, was defined by aggressive commercial activity from a few players, while others remained specters. Pulsetto was the most active, surpassing $40 million in revenue, securing EU funding for trials, and launching a new "FIT X" wearable. It also referenced a 2026 pilot study (an open-label conference abstract) claiming its bilateral cervical stimulation reduced hair cortisol more than unilateral stimulation. Hoolest promoted its VeRelief Prime with discount codes and a gel subscription plan. Vielight confirmed its photobiomodulation-based Vagus device and continued developing its "Vielight-AI" EEG platform, but the platform's commercial launch remains unconfirmed—its webpage carries only a wellness disclaimer. Other devices like Xen by Neuvana and Nurosym confirmed their consumer market presence, while the "SONA AI VNS System" was notable for its absence; searches failed to find a primary source, pointing only to unrelated companies.

Several new or vague entities surfaced purely through deal articles, highlighting the marketing noise in the category. The "Nuropod" device was mentioned only in a Black Friday deal roundup, and the "Vagustim V2" was confirmed via its product page but without independent verification of its claims. This pattern of discovery through promotional content, rather than clinical or primary commercial sources, is a consistent red flag for products in this space.

For someone considering spending money, the landscape is starkly divided. If you are a researcher, there are more sophisticated, parameter-locked taVNS tools than ever. If you are a patient with a specific FDA-cleared condition like cluster headache or rheumatoid arthritis, there are defined, albeit not without regulatory friction, medical pathways. If you are a consumer seeking stress or wellness benefits, you are navigating a market of unverified claims where the loudest marketing and promotional deal cycles are the primary signals of activity, not published, controlled efficacy data. The most concrete developments of the year were in clinical research and regulated medicine; the consumer side remains a realm of vendor assertion.

Written 2026-10-03 from the changelog below, not from a fresh search.

The ones that mattered:

• 2026-10-03 — Pulsetto cites pilot study showing bilateral stimulation reduced hair cortisol. (study, vendor-claim)
• 2026-10-03 — Comprehensive review of taVNS mechanisms and applications published. (study, primary-source)
• 2026-10-03 — taVNS pilot study shows improvement in dysautonomia for hypermobile Ehlers-Danlos patients. (study, primary-source)
• 2026-10-03 — taVNS improves executive control after high cognitive load in randomized study. (study, primary-source)
• 2026-09-21 — Pulsetto launches FIT X, a next-generation wearable with redesigned bilateral electrode. (launch, vendor-claim)
• 2026-09-21 — ElectroCore's stock plunges after FDA requests more data on GammaCore. (regulatory, secondary)
• 2026-09-21 — No primary source found for SONA AI VNS system; LinkedIn points to unrelated companies. (negative, unverified)
• 2026-09-14 — Evren Technologies launches Phoenix CR taVNS research device. (launch, vendor-claim)

All time

The field of consumer-accessible vagus nerve stimulation is splitting into two distinct tracks: medically-regulated devices for specific conditions, and a crowded, evidence-thin wellness market. The most concrete developments are in the clinical and research realm. The FDA-approved SetPoint System, an implantable device for rheumatoid arthritis, saw its first reported clinical use in New Jersey this period, a direct application of the neuroimmune modulation research published in late 2025. For non-invasive clinical research, tools are maturing: Soterix Medical and Evren Technologies both launched dedicated taVNS research devices (the latter called Phoenix CR), while tVNS Technologies GmbH introduced a low-latency "Triggerbox" for precise study synchronization. On the negative side, a systematic review cited this period found no significant difference between VNS and sham for depression in controlled studies, and LivaNova's implantable SenTiva generator remains under a Class 2 FDA recall for a fault that can stop stimulation entirely.

In the consumer wellness segment, electrical ear- or neck-based stimulators are proliferating with vendor claims but little public, primary-source validation. Pulsetto is the most commercially active, announcing it surpassed $40M in revenue, launching a redesigned "FIT X" wearable, and citing a 2026 pilot study (an abstract) showing bilateral neck stimulation reduced hair cortisol. They, along with Hoolest and the newly mentioned Nuropod, are already featured in 2026 Black Friday deal roundups, indicating these are marketing-driven, seasonal products. Hoolest's VeRelief Prime offers a subscription for conductive gel. Other devices like Vagustim V2, Xen by Neuvana, and Nurosym have live sales pages claiming CE marks or wellness benefits, but no new independent data supports their consumer efficacy claims. The SONA AI VNS system appears to be a marketing phantom, with no primary source found despite being listed in roundups.

Photobiomodulation (PBM) presents a non-electrical alternative, anchored by Vielight Vagus. Vielight was awarded a patent for the device this period, which uses near-infrared light pulsed at 100 Hz. Their companion Vielight-AI EEG analysis platform is described in marketing but remains in a "watching" status with no confirmation of a commercial launch. A separate randomized study this period found acute photobiomodulation can affect HRV, providing tangential support for the modality's physiological impact.

The research literature is expanding independently of these products. Recent peer-reviewed studies show promising pilot data for taVNS improving autonomic symptoms in Ehlers-Danlos syndrome and executive control after cognitive load, and a comprehensive review article summarized the mechanisms and clinical potential of taVNS. This science contrasts with the consumer market, where the primary evidence is vendor blogs, coupon codes, and press releases. For a newcomer, the gap is stark: credible research tools and regulated medical devices are evolving with published trials, while the direct-to-consumer "stress relief" segment is a noisy bazaar of similar claims, where shopping during a sales event may be the most documented user behavior.

Written 2026-10-03 from the changelog below, not from a fresh search.

How the field breaks down, by what we're actually tracking:

• electrical — 14 items: Hoolest VeRelief Prime, Hoolest Inc., Soterix Medical Transcutaneous Auricular Vagus Nerve Stimulator, tVNS Technologies GmbH, SetPoint System, LivaNova SenTiva, Vagustim V2, Nurosym, SONA AI Vagus Nerve Stimulation System, Xen by Neuvana, Pulsetto, Evren Phoenix CR, gammaCore, Nuropod.
• photobiomodulation — 1 item: Vielight Vagus.
• measurement — 1 item: Vielight-AI.
• biofeedback — 1 item: HeartMath Inner Balance Coherence Plus.

Tracked products

Available now. Price and regulatory status are blank where we have not read them on a primary source — they are never inferred.

Upcoming

Announced, no date.

Nothing in this bucket right now.

Coming Soon

Announced with a date, or an open pre-order.

Nothing in this bucket right now.

What We're Watching

Exists, unproven, or newly discovered. This is where auto-discovered items land.

Vielight-AI

EEG-analysis platform signalled by Vielight for an early-2026 soft launch; no confirmation it has shipped.

First seen 2026-08-04 · confidence vendor-claim · measurement

Why it's here: Vielight-AI platform page includes wellness disclaimer, not confirming commercial launch. (2026-09-14) — A Vielight page for 'Vielight-AI' describes it as a wellness platform for personal brain health tracking, with a disclaimer stating it is not intended to diagnose, treat, cure, or prevent any disease, but does not confirm it has shipped as a standalone product.

Sources: Vielight

Soterix Medical Transcutaneous Auricular Vagus Nerve Stimulator

A taVNS device based on the mini-CT platform, developed for clinical human brain stimulation research.

First seen 2026-08-04 · confidence unverified · electrical

Why it's here: Clinical trial registered to test Soterix Medical taVNS device for delirium. (2026-09-07) — A study on ClinicalTrials.gov details a trial using the Soterix Medical Transcutaneous Auricular Vagus Nerve Stimulator to treat delirium, with an FDA non-significant risk designation.

Sources: Product page

tVNS Technologies GmbH

Company offering a non-invasive vagus nerve stimulation device approved as a medical device under the EU-MDR.

First seen 2026-08-04 · confidence unverified · electrical

Why it's here: tVNS Technologies GmbH states its tVNS device is approved as a Class IIa medical device under EU-MDR. (2026-08-24) — The company's physician-facing page confirms its tVNS device is approved as a Class IIa medical device under the European Medical Device Regulation (MDR).

Sources: Company website

SetPoint System

An implantable vagus nerve stimulation device FDA-approved for the treatment of rheumatoid arthritis.

First seen 2026-08-04 · confidence unverified · electrical

Why it's here: SetPoint System used for rheumatoid arthritis at New Jersey medical center. (2026-10-03) — Overlook Medical Center is reported as the first in New Jersey to use the FDA-approved SetPoint System, an implantable vagus nerve stimulator, for rheumatoid arthritis treatment.

Sources: Medscape article

LivaNova SenTiva

An implantable vagus nerve stimulation generator for epilepsy, subject to a Class 2 FDA recall.

First seen 2026-08-04 · confidence unverified · electrical

Why it's here: LivaNova recalls SenTiva vagus nerve stimulator generators due to risk of stopping stimulation. (2026-08-04) — A Class 2 Device Recall was issued for SenTiva generators because an internal component may become stuck, causing the device to stop delivering stimulation.

Sources: FDA Recall Notice

Vagustim V2

A personalized vagus nerve stimulator with mobile app integration for real-time control and session monitoring.

First seen 2026-08-18 · confidence unverified · electrical

Why it's here: Vagustim V2 product page confirms it as a non-invasive, ear-based VNS device. (2026-09-21) — The Vagustim.io website markets Vagustim V2 as a non-invasive vagus nerve stimulation device that sends gentle electrical pulses through the ear to activate the vagus nerve.

Sources: Product page

Nurosym

A CE-marked auricular transcutaneous vagus nerve stimulator (tVNS) marketed for home use.

First seen 2026-08-18 · confidence unverified · electrical

Why it's here: Nurosym website active with marketing and user testimonials. (2026-08-31) — The Nurosym website is live with marketing content, user testimonials, and a claim of CE-marked status for home-use auricular tVNS, though this is not new information versus the existing changelog.

Sources: Official store · Blog article on device status

HeartMath Inner Balance Coherence Plus

An HRV sensor and biofeedback tool designed to train heart-brain coherence for stress reduction and resilience.

First seen 2026-08-18 · confidence unverified · biofeedback

Why it's here: HeartMath launches Inner Balance Coherence Plus HRV biofeedback sensor. (2026-08-18) — HeartMath's store page presents the Inner Balance Coherence Plus, an HRV sensor and biofeedback tool designed to train the nervous system for lower stress and better health.

Sources: Product page

SONA AI Vagus Nerve Stimulation System

An AI-powered vagus nerve stimulation system referenced in 2026 marketing but with no primary source or product page found.

First seen 2026-08-31 · confidence unverified · electrical

Why it's here: No primary source found for SONA AI VNS system; LinkedIn points to unrelated companies. (2026-09-21) — Search results for 'SONA' return links to a workforce management software company and a video game character, but no primary product page or evidence of a commercial launch for the AI-powered VNS system.

Sources: Marketing blog mention

Evren Phoenix CR

A transcutaneous auricular vagus nerve stimulator (taVNS) research tool designed for clinical human brain stimulation studies.

First seen 2026-09-14 · confidence unverified · electrical

Why it's here: Evren Technologies launches Phoenix CR taVNS research device. (2026-09-14) — Evren Technologies announced the launch of its Phoenix CR System, a transcutaneous auricular vagus nerve stimulator (taVNS) designed as a research tool for clinical human brain stimulation studies.

Sources: Product page

Nuropod

A consumer vagus nerve stimulation device referenced in Black Friday deal articles.

First seen 2026-10-03 · confidence unverified · electrical

Why it's here: No changelog entry explains this status yet.

Sources: none recorded — this item is a name we've seen and not much more.

Promising

Early-stage, but the evidence or the approach is genuinely interesting. The only editorial bucket on this page — an item only lands here with a reason recorded in the changelog.

Nothing in this bucket right now.

Open questions

Publishing what we don't know is the point. These are things the job is actively watching for; when one gets answered it becomes a changelog entry and moves down here to the answered list.

• What is the VeRelief Prime's current FDA/regulatory posture — cleared, registered, or a general-wellness device outside device regulation? — open since 2026-08-04.
• Did Vielight-AI actually ship, and what does it do with EEG data? — open since 2026-08-04.
• Is there any head-to-head evidence between electrical vagal stimulation and photobiomodulation approaches, or are the literatures disjoint? — open since 2026-08-04.

Answered:

• What does the Hoolest VeRelief Prime actually cost, from a primary source? — answered 2026-08-04.

Full changelog

Everything, newest first, grouped by the month we found it. Long by design — it's the receipts.

October 2026

September 2026

August 2026

Dreamlab Live Research uses autonomous systems to track the state of the art in fields of interest. New trackers appear as the interests do.

Generated from a versioned dataset in a git repository: every state this page has ever been in is a commit, and a bad run is revertible. The dataset is the source; this page is build output and is not itself edited.

• Dataset: data/live-research/vagus.json (schema version 2)
• Runs completed: 10 · cadence: weekly
• Items tracked: 17 · changelog entries: 42
• Distinct sources seen: 359
• Last run recorded: 2026-10-03T04:36:44Z (status: ok)